about
MRI correlates of disability progression in patients with CIS over 48 months.Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis.Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromesHLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating eventTwo-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells
P50
Q34431806-DBFDA475-7EBA-4280-A606-76C0B1D91F0BQ34483022-CE92C299-2216-45AB-8033-FC118E29BF89Q34548374-7506C1BA-D596-4A9B-8118-07BCDDF58B72Q36093231-20CEE5C5-64EE-46F0-8725-B1B540D6D9C9Q47924597-FA6132C9-9A31-4758-9BBD-3E854410286DQ48088336-8477F505-5C8A-49D4-8BB6-52AC902B1548Q48108313-1DAE322B-004B-45B8-BBC8-21339110965FQ48215414-B8EF284E-DD8B-4B8D-8F87-FF6D4186E61BQ48431460-6346611E-AAA5-4993-A1B4-0DD897EB82C9Q48704199-A9D98658-1A5E-48B1-AE3F-5141DA1A226AQ48711608-9041AFFF-6287-4F3B-8EA7-3A958C92E670Q48901292-596100A0-8359-4A1C-9D4B-A62F47993E04Q50666756-367C0ACC-73CC-4496-9313-BDFAC5183E54Q51062974-14EF209B-6C3E-4444-B3C3-46691E005C3CQ51249160-66FD1EA0-BA2B-4EDF-B5C7-F1F18520903DQ52141693-D30435E1-C48F-4277-89D8-0AB4951F538EQ52149416-2467359A-2E3B-4AF6-BC85-31F20E2C86DDQ61037588-C49983A2-CE3D-4430-8329-1BA2F4415E4BQ61037598-24FC3443-D72B-4254-BE8B-F75A8DC81C1BQ86034352-CC105B46-2CEF-41C8-953D-F5F7C7D533CD
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Michaela Tyblova
@ast
Michaela Tyblova
@en
Michaela Tyblova
@es
Michaela Tyblova
@nl
Michaela Tyblova
@sl
Michaela Týblová
@cs
type
label
Michaela Tyblova
@ast
Michaela Tyblova
@en
Michaela Tyblova
@es
Michaela Tyblova
@nl
Michaela Tyblova
@sl
Michaela Týblová
@cs
prefLabel
Michaela Tyblova
@ast
Michaela Tyblova
@en
Michaela Tyblova
@es
Michaela Tyblova
@nl
Michaela Tyblova
@sl
Michaela Týblová
@cs
P214
P106
P1153
6507517204
P21
P214
P31
P496
0000-0002-9091-8629